TriSalus Life Sciences Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has created a New Technology Healthcare Common Procedure Coding System (HCPCS) code for procedures involving the TriNav® Infusion System. This new code, HCPCS C9797, has been assigned to the Ambulatory Payment Classification (APC) 5194 - Level 4 Endovascular Procedures. The new code will become effective on January 1, 2024, and may be reported by hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | +1.95% | +1.41% | -31.83% |
06-03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
05-30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.83% | 153M | |
+16.13% | 122B | |
+19.65% | 115B | |
+21.22% | 26.64B | |
-23.84% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-19.28% | 15.49B | |
+63.81% | 14.83B | |
+1.94% | 13.67B |
- Stock Market
- Equities
- TLSI Stock
- News TriSalus Life Sciences, Inc.
- TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of New Technology Healthcare Common Procedure Coding System Code